

Andrew H Talal

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5060334/publications.pdf>

Version: 2024-02-01

50
papers

1,687
citations

430442

18
h-index

276539

41
g-index

50
all docs

50
docs citations

50
times ranked

2734
citing authors

#	ARTICLE	IF	CITATIONS
1	Patient-centered HCV care via telemedicine for individuals on medication for opioid use disorder: Telemedicine for Evaluation, Adherence and Medication for Hepatitis C (TEAM-C). <i>Contemporary Clinical Trials</i> , 2022, 112, 106632.	0.8	7
2	Facilitating engagement of persons with opioid use disorder in treatment for hepatitis C virus infection via telemedicine: Stories of onsite case managers. <i>Journal of Substance Abuse Treatment</i> , 2021, 127, 108421.	1.5	5
3	Fine-Needle Aspiration for the Evaluation of Hepatic Pharmacokinetics of Vaniprevir: A Randomized Trial in Patients With Hepatitis C Virus Infection. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 107, 1325-1333.	2.3	0
4	Assessing routes of hepatitis C transmission in HIV-infected men who have sex with men using single genome sequencing. <i>PLoS ONE</i> , 2020, 15, e0235237.	1.1	6
5	A framework for patient-centered telemedicine: Application and lessons learned from vulnerable populations. <i>Journal of Biomedical Informatics</i> , 2020, 112, 103622.	2.5	33
6	Age- and risk factor-based serologic screening for Hepatitis C virus among an Urban, high-risk population. <i>Journal of Viral Hepatitis</i> , 2020, 27, 1369-1387.	1.0	0
7	Intrahepatic Viral Kinetics During Direct-Acting Antivirals for Hepatitis C in Human Immunodeficiency Virus Coinfection: The AIDS Clinical Trials Group A5335S Substudy. <i>Journal of Infectious Diseases</i> , 2020, 222, 601-610.	1.9	7
8	Toward precision prescribing for methadone: Determinants of methadone deposition. <i>PLoS ONE</i> , 2020, 15, e0231467.	1.1	14
9	Influence of social determinants of health and substance use characteristics on persons who use drugs pursuit of care for hepatitis C virus infection. <i>Journal of Substance Abuse Treatment</i> , 2019, 102, 33-39.	1.5	14
10	Efficacy and safety of glecaprevir/pibrentasvir in patients with chronic HCV infection and psychiatric disorders: An integrated analysis. <i>Journal of Viral Hepatitis</i> , 2019, 26, 951-960.	1.0	21
11	Integrated, Co-located, Telemedicine-based Treatment Approaches for Hepatitis C Virus Management in Opioid Use Disorder Patients on Methadone. <i>Clinical Infectious Diseases</i> , 2019, 69, 323-331.	2.9	50
12	Patient Reaction to Telemedicine for Clinical Management of Hepatitis C Virus Integrated into an Opioid Treatment Program. <i>Telemedicine Journal and E-Health</i> , 2019, 25, 791-801.	1.6	25
13	Hepatic Pharmacokinetics and Pharmacodynamics With Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir Treatment and Variable Ribavirin Dosage. <i>Journal of Infectious Diseases</i> , 2018, 217, 474-482.	1.9	5
14	Genetic Variation at IFNL4 Influences Extrahepatic Interferon-Stimulated Gene Expression in Chronic HCV Patients. <i>Journal of Infectious Diseases</i> , 2018, 217, 650-655.	1.9	17
15	Improvements in Quality of Life: A New Indication for Treating Hepatitis C Virus Infection in Persons With Substance Use Disorders. <i>Journal of Infectious Diseases</i> , 2018, 217, 1020-1023.	1.9	6
16	Hepatitis C virus knowledge improves hepatitis C virus screening practices among primary care physicians. <i>World Journal of Hepatology</i> , 2018, 10, 319-328.	0.8	18
17	Intrahepatic Sampling for the Elucidation of Antiviral Clinical Pharmacology. <i>Clinical Pharmacology in Drug Development</i> , 2017, 6, 169-175.	0.8	2
18	Hepatitis C virus core antigen: A potential alternative to HCV RNA testing among persons with substance use disorders. <i>Journal of Substance Abuse Treatment</i> , 2017, 78, 37-42.	1.5	8

#	ARTICLE	IF	CITATIONS
19	Toward Optimal Control of Hepatitis C Virus Infection in Persons With Substance Use Disorders. <i>Annals of Internal Medicine</i> , 2017, 166, 897.	2.0	16
20	Medical and Behavioral Approaches to Engage People Who Inject Drugs Into Care for Hepatitis C Virus Infection. <i>Addictive Disorders and Their Treatment</i> , 2017, 16, S1-S23.	0.5	29
21	Ultra-performance liquid chromatography tandem mass spectrometry for determination of Direct Acting Antiviral drugs in human liver fine needle aspirates. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2017, 1052, 103-109.	1.2	14
22	Paritaprevir and Ritonavir Liver Concentrations in Rats as Assessed by Different Liver Sampling Techniques. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	4
23	Assessment of Hepatic Impairment and Implications for Pharmacokinetics of Substance Use Treatment. <i>Clinical Pharmacology in Drug Development</i> , 2017, 6, 206-212.	0.8	29
24	Drug-Drug Interactions and Diagnostics for Drug Users With HIV and HIV/HCV Coinfections: Introduction. <i>Clinical Pharmacology in Drug Development</i> , 2017, 6, 108-117.	0.8	0
25	Diagnostic accuracy of intracellular uptake rates calculated using dynamic Gd-enhanced MRI for hepatic fibrosis stage. <i>Journal of Magnetic Resonance Imaging</i> , 2017, 45, 1177-1185.	1.9	25
26	Improvements in HCV-related Knowledge Among Substance Users on Opioid Agonist Therapy After an Educational Intervention. <i>Journal of Addiction Medicine</i> , 2016, 10, 104-109.	1.4	16
27	Development and validation of a UPLC-MS/MS method for the simultaneous determination of paritaprevir and ritonavir in rat liver. <i>Bioanalysis</i> , 2016, 8, 1353-1363.	0.6	12
28	Liver-to-Plasma Vaniprevir (MK-7009) Concentration Ratios in HCV-Infected Patients. <i>Antiviral Therapy</i> , 2015, 20, 843-848.	0.6	14
29	Intrahepatic and Peripheral CXCL10 Expression in Hepatitis C Virus-Infected Patients Treated With Telaprevir, Pegylated Interferon, and Ribavirin. <i>Journal of Infectious Diseases</i> , 2015, 211, 1795-1799.	1.9	10
30	IFN- γ -Induced Downregulation of miR-221 in Dendritic Cells: Implications for HCV Pathogenesis and Treatment. <i>Journal of Interferon and Cytokine Research</i> , 2015, 35, 698-709.	0.5	12
31	Host Genetic Factors and Dendritic Cell Responses Associated with the Outcome of Interferon/Ribavirin Treatment in HIV-1/HCV Co-Infected Individuals. <i>Journal of Clinical & Cellular Immunology</i> , 2014, 05, .	1.5	1
32	Hepatitis C Virus-Related Knowledge and Willingness to Receive Treatment Among Patients on Methadone Maintenance. <i>Journal of Addiction Medicine</i> , 2014, 8, 249-257.	1.4	37
33	Telaprevir-based treatment effects on hepatitis C virus in liver and blood. <i>Hepatology</i> , 2014, 60, 1826-1837.	3.6	22
34	Assessment of methadone clinic staff attitudes toward hepatitis C evaluation and treatment. <i>Journal of Substance Abuse Treatment</i> , 2013, 44, 115-119.	1.5	10
35	Dendritic Cells in HIV-1 and HCV Infection: Can They Help Win the Battle?. <i>Virology: Research and Treatment</i> , 2013, 4, VRT.S11046.	3.5	8
36	Hepatitis C virus control among persons who inject drugs requires overcoming barriers to care. <i>World Journal of Gastroenterology</i> , 2013, 19, 7846.	1.4	74

#	ARTICLE	IF	CITATIONS
37	Genome-Wide Association Study Identifies Variants Associated With Progression of Liver Fibrosis From HCV Infection. <i>Gastroenterology</i> , 2012, 143, 1244-1252.e12.	0.6	142
38	Induction of CXCR3- and CCR5-associated chemokines during acute hepatitis C virus infection. <i>Journal of Hepatology</i> , 2011, 55, 545-553.	1.8	34
39	Randomized Trial Comparing Dose Reduction and Growth Factor Supplementation for Management of Hematological Side Effects in HIV/Hepatitis C Virus Patients Receiving Pegylated-Interferon and Ribavirin. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2011, 58, 261-268.	0.9	10
40	Hepatitis C virus infection in USA: an estimate of true prevalence. <i>Liver International</i> , 2011, 31, 1090-1101.	1.9	355
41	Intrahepatic levels of CXCR3-associated chemokines correlate with liver inflammation and fibrosis in chronic hepatitis C. <i>Hepatology</i> , 2008, 48, 1440-1450.	3.6	194
42	Noninjection drug use: an underappreciated risk factor for hepatitis C virus transmission. <i>Liver International</i> , 2008, 28, 757-760.	1.9	16
43	A Hepatitis C Viral Kinetic Model that Allows for Time-Varying Drug Effectiveness. <i>Antiviral Therapy</i> , 2008, 13, 919-926.	0.6	22
44	Interferon β -Inducible Protein 10. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2007, 45, 262-268.	0.9	53
45	Pharmacodynamics of PEG-IFN α differentiate HIV/HCV coinfecting sustained virological responders from nonresponders. <i>Hepatology</i> , 2006, 43, 943-953.	3.6	81
46	Plasma chemokine levels correlate with the outcome of antiviral therapy in patients with hepatitis C. <i>Blood</i> , 2005, 106, 1175-1182.	0.6	168
47	Virus Dynamics and Immune Responses During Treatment in Patients Coinfected With Hepatitis C and HIV. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2004, 35, 103-113.	0.9	26
48	Opportunistic infections in HIV-infected individuals: hepatitis C virus. <i>Lancet, The</i> , 2002, 360, 584-586.	6.3	10
49	The HCV and HIV coinfecting patient: What have we learned about pathophysiology?. <i>Current Gastroenterology Reports</i> , 2002, 4, 15-22.	1.1	5
50	Hepatitis C Virus Treatment Delivered via Telemedicine to Persons With Opioid Use Disorder. <i>JAMA Internal Medicine</i> , 0, , .	2.6	0